Rapross Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 2.50 M
as on 24-10-2024
- Company Age 29 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 5.00 Cr
as on 24-10-2024
- Revenue 2.73%
(FY 2023)
- Profit -3.90%
(FY 2023)
- Ebitda 22.62%
(FY 2023)
- Net Worth 11.86%
(FY 2023)
- Total Assets 29.08%
(FY 2023)
About Rapross Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 2.50 M.
The company has closed loans amounting to ₹5.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ranjan Verma, Karam Verma, Parveen Bansal, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74899DL1995PTC066606
- Company No.
066606
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Mar 1995
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Rapross Pharmaceuticals Private Limited offer?
Rapross Pharmaceuticals Private Limited offers a wide range of products and services, including Diclofenac, Diclofenac Sodium Injection, Common Disease Medicines, Pharmaceutical Medicine, Vitamin Tablets & Capsules, Cholecalciferol Granules.
Who are the key members and board of directors at Rapross Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ranjan Verma  | Director | 04-Apr-1995 | Current |
| Parveen Bansal | Director | 04-Apr-1995 | Current |
| Karam Verma | Additional Director | 08-Feb-2024 | Current |
| Sharad Verma | Additional Director | 01-Sep-2023 | Current |
| Nimit Bansal | Additional Director | 01-Sep-2023 | Current |
Financial Performance of Rapross Pharmaceuticals.
Rapross Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.73% increase. The company also saw a slight decrease in profitability, with a 3.9% decrease in profit. The company's net worth Soared by an impressive increase of 11.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rapross Pharmaceuticals?
Unlock access to Rapross Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 04 Jul 2022 | ₹5.00 Cr | Satisfied |
How Many Employees Work at Rapross Pharmaceuticals?
Rapross Pharmaceuticals has a workforce of 295 employees as of Sep 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rapross Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rapross Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
